Kinnate BioPharma Inc.

General Information
Business:

We are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products for underserved populations. We utilize our deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, which we collectively refer to as our Kinnate Discovery Engine, to develop our targeted therapies.

Our most advanced product candidate is KIN002787, which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor we are developing for the treatment of patients with lung cancer, melanoma and other solid tumors. 

(Note: The deal was upsized at pricing: 20 million shares (vs. 11.5 million filed) – priced at $20 (above the new range of $18-$19), after the deal was increased by 25 percent in an SEC filing on Dec. 2, 2020.)

Industry: Pharmaceuticals
Employees: 27
Founded: 2018
Contact Information
Address 11975 El Camino Real, Suite 101 San Diego, CA 92130
Phone Number (858) 299-4699
Web Address http://www.kinnate.com
View Prospectus: Kinnate BioPharma Inc.
Financial Information
Market Cap $830.5mil
Revenues $0 mil (last 12 months)
Net Income $-26.1 mil (last 12 months)
IPO Profile
Symbol KNTE
Exchange NASDAQ
Shares (millions): 12.0
Price range $20.00 - $20.00
Est. $ Volume $240.0 mil
Manager / Joint Managers Goldman Sachs/ SVB Leerink/ Piper Sandler
CO-Managers Wedbush PacGrow
Expected To Trade: 12/3/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change